Acute Myeloid Leukemia (AML) Treatment Market Highlights 2020-2029
The acute myeloid leukemia (AML) treatment market is estimated to garner a notable revenue by growing at a significant CAGR over the forecast period, i.e., 2021-2029. The growth of the market can be attributed to the growing concerns for the increasing cancer mortality rate and the rising prevalence of acute myeloid leukemia around the world. As per the statistics of World Health Organization, cancer is the second leading cause of death, and is responsible for about one out of every six deaths globally. Moreover, according to the statistics by the National Cancer Institute (NCI) of the U.S. Department of Health and Human Services, AML contributes to 1.8% of all cancer deaths in the United States. Furthermore, high occurrence of cancer cases and low survival rate is estimated to generate ample opportunities for the growth of the global AML treatment market by the end of 2029. In the other statistics by the NCI, the survival rate for adults with AML is 28%. Moreover, more than 19,500 new cases of AML occur every year in the United States. Additionally, around 64,512 people in the U.S. were living with AML, as of 2017.
The market is segmented by disease type into promyelocytic, myeloblastic, myelomonocytic, monocytic and others. Based on treatment type, the market is further segmented into chemotherapy, stem cell transplantation, anticancer drugs, and others. Out of these, the chemotherapy segment holds the largest market share in 2021 on the back of its popularity as cancer treatment. However, the stem cell transplantation segment is estimated to emerge with a promising CAGR during the forecast period, on the back of ongoing research and medical advancements regarding stem cell transplants. Alternatively, the anticancer drugs segment, which includes specific drugs for the treatment of AML, such as arsenic trioxide or trans-retinoic acid, targets specific mutations of leukemia cells in rare cases, and is projected to hold a significant revenue share by the end of 2029.
Global AML Treatment Market Regional Synopsis
Regionally, the global AML treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
Among the market in these regions, the market in North America is anticipated to account for the largest share by the end of 2029 in the global acute myeloid leukemia treatment market. Increased government funding in R&D activities, a well-developed public healthcare sector and elevated disposable income of the people in the region are the major factors expected to drive the market growth during the forecast period. According to the data by the World Health Organization (WHO), as of 2018, 16.416 % of the GDP is spent on health sector in North America. Moreover, people-friendly medical reimbursement policies are also estimated to boost the market growth in North America. The market in Europe, on the other hand, is estimated to be a promising market owing to the high healthcare expenditure in the region. Moreover, the growth of the market is encouraged by the availability of a large geriatric population in the region. As of 2019, over 20% of the total population in Southern Europe was aged 65 years and above.
Moreover, the market share of Asia Pacific is expected to grow notably during the forecast period due to the enormous unmet potential present in the healthcare sector of the region. The rapid economic development combined with a growing demand for advanced healthcare system is likely to encourage considerable growth for the APAC region.
The global AML treatment market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Market Segmentation
Our in-depth analysis of the global AML treatment market includes the following segments:
By Disease Type
- Promyelocytic
- Myeloblastic
- Myelomonocytic
- Monocytic
- Others
By Treatment
- Chemotherapy
- Cytarabine
- Anti-metabolites
- Anthracycline Drugs
- Tyrosine Kinase Inhibitors
- Alkylating Agents
- Hormonal Therapy
- Others
- Stem Cell Transplantation
- Anticancer Drugs
- Others
By End-User
- Hospitals
- Specialty Clinics
- Others
Growth Drivers
- Rising Prevalence of Acute Myeloid Leukemia
- Government Initiatives for Cancer Prevention
Challenges
- High Treatment Costs and Unavailability of the Treatment in Several Developing Nations
- Side Effects Associated with Existing Treatment Methods
Top Featured Companies Dominating the Market
The major industry leaders in the global acute myeloid leukemia (AML) treatment market are Novartis AG, Pfizer Inc. and Johnson & Johnson Services Inc. who are manufacturing FDA-approved AML treatment drugs. Other than these, many manufacturers such as Cyclacel Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi-aventis Groupe, and Eisai Co. Ltd. are involved in the research and development of AML treatment drug, with their drugs undergoing the different phases of clinical trials. Additionally, the market is estimated to witness increased competition among the key players in the upcoming years owing to the increased investment in R&D and for the interest of several new players to enter the market.
